Alternatives to Paxlovid for COVID-19 Treatment
Primary Alternative: Remdesivir
- The World Health Organization suggests remdesivir as the primary alternative to Paxlovid for high-risk patients with non-severe COVID-19, due to its superior efficacy and safety profile compared to molnupiravir 1, 2
- Remdesivir probably results in an important reduction in hospital admission risk, with moderate certainty evidence 2
- Remdesivir demonstrates little or no impact on mortality, mechanical ventilation, or time to symptom resolution, with moderate to low certainty evidence 2
- In high-risk patients, remdesivir reduced progression to severe COVID-19/hospitalization from 5.3% to 0.7% 3, 4
- Among immunocompromised patients, remdesivir was independently associated with lower mortality risk 3, 4
Secondary Alternative: Molnupiravir
- Molnupiravir should only be used when both Paxlovid and remdesivir are unavailable or contraindicated, and only in high-risk patients, due to its inferior efficacy and safety concerns compared to remdesivir 1
- The World Health Organization suggests molnupiravir may be used in high-risk patients, but with significant concerns about toxicity that will outweigh benefits for many patients 1
- Molnupiravir is inferior to Paxlovid, making little or no difference to mortality, and probably has less benefit in reducing hospitalization 1
- Molnupiravir reduced hospitalization/death from 9.7% to 6.8% in clinical trials 3, 4
- Molnupiravir is contraindicated in pregnancy and breastfeeding, and men of reproductive age must use reliable contraception during treatment and for at least 3 months after the last dose 1
Monoclonal Antibodies
- Anti-spike monoclonal antibodies may benefit immunocompromised patients who fail to develop humoral responses, but their use is highly dependent on circulating viral variants 3, 4
- Previously available agents showed efficacy in reducing progression to severe COVID-19 or death, but their activity is affected by specific viral mutations 3, 4
- The choice of monoclonal antibody must be based on local availability, national approval, and updated epidemiology of circulating variants 3, 4
Clinical Decision Algorithm
- When Paxlovid is contraindicated or unavailable, remdesivir is the first-line alternative, preferred for patients with CYP3A4 drug interactions, pregnant patients, and children 1, 2
- Molnupiravir is the second-line alternative, only for high-risk patients, and contraindicated in pregnancy, breastfeeding, and men not using contraception 1, 2
- Variant-specific monoclonal antibodies should be considered for immunocompromised patients 3, 4
COVID-19 Treatment with Paxlovid and Molnupiravir
Comparative Efficacy
- The World Health Organization recommends Paxlovid over molnupiravir for treating COVID-19 in high-risk patients, with greater reductions in hospitalization and mortality, and a better safety profile 5, 6
- Paxlovid demonstrates superior efficacy in preventing hospitalization compared to molnupiravir, with moderate certainty evidence showing greater absolute risk reduction 5, 6
- Direct comparison evidence indicates remdesivir may result in larger reductions in hospitalization than molnupiravir, and Paxlovid likely performs similarly or better than remdesivir 5
Safety Profile
- Molnupiravir carries serious genotoxicity concerns based on preclinical data showing potential for malignancy, mutagenesis, and reproductive harm 6
- The primary safety concern with Paxlovid is drug-drug interactions due to ritonavir's CYP3A4 inhibition, not genotoxicity, as stated by the American College of Clinical Pharmacy 5
Clinical Decision Algorithm
- Remdesivir is the preferred alternative to Paxlovid when drug interactions are problematic, not molnupiravir, according to the Infectious Diseases Society of America 5
- The WHO conditionally recommends against Paxlovid for moderate-risk patients and suggests not using it for low-risk patients, as benefits do not outweigh harms and costs 7, 5
Risk Stratification for Treatment
- The Centers for Disease Control and Prevention suggests that high-risk criteria for treatment include age ≥65 years, immunocompromised status, unvaccinated or vaccine non-responders, and chronic medical conditions, although this information is not directly cited 5
- However, The WHO suggests that Paxlovid should be used in high risk patients, as stated by the European Society of Clinical Microbiology and Infectious Diseases 5, 6
WHO Guidance on Oral Antiviral Choice for Non‑Severe COVID‑19 in High‑Risk Adults
Comparative Efficacy
WHO Treatment Hierarchy
Safety Profile of Molnupiravir
Strength of Recommendations by Risk Category
| Patient‑risk level | WHO recommendation for Paxlovid | WHO recommendation for Molnupiravir | Evidence certainty |
|---|---|---|---|
| High risk (≥ 65 y, immunocompromised, unvaccinated, chronic disease) | Strong recommendation (preferred first‑line) | Conditional recommendation; use only if Paxlovid and remdesivir unavailable | Moderate‑certainty for efficacy; very low‑certainty for safety of molnupiravir |
| Moderate risk | Conditional recommendation (may be used based on individual factors) | Conditional recommendation AGAINST; “does not have an important impact on mortality and results in little or no reduction in hospital admission” | High certainty |
| Low risk | Strong recommendation AGAINST (no benefit) | Strong recommendation AGAINST; “high certainty of trivial benefit and serious concerns about possible long‑term harms” | High certainty |